Alemania

Artículos Recientes

•  

  29.03.2023

  Europe

  Of­f­sho­re Wi­nd in No­r­way – Fi­r­st Rou­nd An­nou­n­ced

  Live-streaming from an electrical, carbon fibre catamaran, Norwegian Prime Minister Jonas Gahr Støre and Minister of Petroleum & Energy Terje Aasland announced today the long awaited first tender process for offshore wind. This first round, catering for approximately 3 GW of offshore wind, is the first step towards the Norwegian government's long-term ambition to allocate areas for 30 GW offshore wind by 2040.A number of offshore wind consortia have been established in anticipation of this first round and we expect to see fierce competition over the four project areas up for award. The...

  Leer más
•  

  28.03.2023

  Europe

  Eu­ro­pean Pa­r­lia­me­nt and Coun­cil ready to sta­rt ne­go­tia­tio­ns on EU Da­ta Act – Eu­ro­pe ge­ts clo­ser to ado­p­ti­ng a da­ta law

  In February 2022 the European Commission presented its proposal for the EU Data Act, which – if adopted - will introduce a far-reaching legal regime on access to and use of non-personal data in the EU and will, similar to the GDPR, be applicable to businesses established outside the EU. The proposed regulation contains a set of rules defining how various forms of data can be used and by whom for purposes across all economic sectors with the aim of creating a new data-agile ecosystem. While the new law will bring new opportunities, it will also create legal challenges for all actors in the...

  Leer más
•  

  24.03.2023

  International

  CMS Eu­ro­pean M&A Stu­dy 2023: Re­co­rd nu­m­ber of dea­ls la­st year de­s­pi­te cha­l­le­n­gi­ng eco­no­mic ba­c­k­d­rop

  The CMS Corporate/M&A Group is pleased to launch the 15th edition of the European M&A StudyIt has been a challenging year for M&A in view of rising inflation and interest rates, slowing growth and increased geopolitical tension, which have added up to a difficult macroeconomic environment. However, there have been plenty of deal opportunities, as demonstrated by the fact that our study covers a record 509 M&A transactions on which CMS advised in 2022. In a difficult M&A market, we are pleased with this result, which reflects the strength of our corporate offering throughout...

  Leer más
•  

  23.03.2023

  Europe

  Eu­ro­pean Pa­te­nt Of­fi­ce (EPO) di­g­gi­ng its hea­ls in over the need for de­s­c­ri­p­tion ame­n­d­me­n­ts, but how to do this re­mai­ns a cha­l­le­n­ge

  As a complement to the 10th edition of the EPO "Case Law of the Boards of Appeal" (CLB), the EPO has published an Annual Review containing summaries of decisions from 2022. The review provides a thematic overview of selected decisions of the boards of appeal published in 2022. There are a number of notable decisions in the summary including those concerning the controversial topic of bringing the description into line with amended claims.BackgroundIn October 2020, CMS published an article ‘New EPO Guidelines expected regarding amending a description: what’s all the fuss about?’,...

  Leer más
•  

  22.03.2023

  Europe

  Eu­ro­pean Pa­te­nt Of­fi­ce (EPO) le­vel of di­s­c­lo­su­re re­qui­red for an­ti­bo­dies - fi­r­st me­di­cal use

  As a complement to the 10th edition of the EPO "Case Law of the Boards of Appeal" (CLB), the EPO has published an Annual Review containing summaries of decisions from 2022. The review provides a thematic overview of selected decisions of the Boards of Appeal published in 2022. There are a number of notable decisions in the summary, although it has been a somewhat quiet year for significant decisions in the antibody area.  Most decisions in this technical area consolidate what is now fairly settled practice at the EPO for antibody cases, where inventive step continues to be a major challenge....

  Leer más
•  

  22.03.2023

  Europe

  Is a pa­tie­nt in a cli­ni­cal trial co­n­si­de­red to be a me­m­ber of the pu­b­lic in the co­n­te­xt of no­ve­l­ty prior art?

  In T 0670/20, the question was whether the internal structure of medicinal tablets had been made available to the public by patients taking part in clinical trials involving administration of the tablets. The Appeal Board found that the patients participating in the trial had entered into a special relationship with the investigators of the trials and were not free to dispose of the tablets. Accordingly, the patients were not members of the public for novelty purposes.However, the Board acknowledged that the patients were not under a duty of confidence with respect to their participation to the...

  Leer más